Novartis Says Diovan Successful in Japanese Patients
Posted on: Friday, 27 April 2007, 12:00 CDT
A large study examining the cardiovascular drug Diovan in Japanese patients has demonstrated a significant reduction in blood pressure and protection of organs, according to the drug's manufacturer Novartis.
In the study, Diovan was added to conventional therapy to control blood pressure and protect against cardiovascular events and stroke. The results showed significant benefit with the use of, including a 39% decrease in cardiovascular events and a 40% decrease in stroke compared to conventional non-ARB therapy.
Furthermore, treatment was initiated in a population with an average starting blood pressure of 139/81 mmHg - already below the national guideline level for hypertension without comorbidities. The blood pressure target was set at 130/80 mmHg. The non-ARB group achieved 132/78 mmHg and the Diovan group achieved 131/77 mmHg. The Diovan group also showed a 65% reduction in angina pectoris, 46% in heart failure and 81% in aortic dissection.
The study was terminated earlier than anticipated due to superior outcomes for the Diovan group over the control group.
Source: Datamonitor
Related Articles
- NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
- Boehringer's Blood Pressure Drug Cuts Down Cardiovascular Risks
- Blood Sugar Study in Diabetics Halted
- National Heart Lung and Blood Institute Creates National Network to Study Cardiovascular Disease
- Overall Blood Pressure Levels Falling, Study Shows
- Blood Substitute Study Draws Criticism
- Speedel drug lowers blood pressure at night -study
- Painkillers raise blood pressure in women-U.S. study
- Biopure, Navy Seek Blood-Substitute Study
- Infants Needing a Heart Transplant Can Accept Organs From Different Blood Types, Study to Be Presented at ISHLT
 |
 |
User Comments (0)
RSS Feeds